Linear amplification patents by Russell Van Gelder, James Eberwine, and others. These include not only the patents at issue in the Incyte-Affymetrix litigation, US Patent Numbers 5,716,785 and 5,891,636, but also US Patent Number 5,545, 522, Process for amplifying a target polynucleotide sequence using a single-primer promoter complex. These patents cover the popular T7 Eberwine protocol for linear amplification, and has already been licensed to Merck among others.
An RNA amplification patent by Incyte scientist Bruce Wang, Method for unbiased mRNA amplification. The patent, number 5,932,451, details an invention for converting mRNA to ds cDNA using a primer with an RNA polymerase site and a priming site, then asymetrically amplifying the ds cDNA.
Dari Shalon and Pat Browns patents for spotting array technologies developed at Stanford, including US Patent Numbers 6,110,426, and 5,807,522, both entitled Methods for fabricating microarrays of biological samples. These patents are regarded as seminal intellectual property for spotted arrays. Gene Machines licensed the patents in July.
Patents by that cover in situ synthesis of nucleic acid microarrays from Ronald Gamble, Thomas Theriault, and John Baldeschwieler. These patents all cover deposition devices for spotting microarrays by shooting a sample through a jet via an electric pulse. They include US Patent Number 5,981,733, Apparatus for the chemical synthesis of molecular arrays, US Patent Numbers 5,847,105 and 6,015,880, Methods for performing multiple sequential reactions on a matrix, and US Patent Number 6,001,309, Jet droplet device.
Leonard Augenlichts patent for distinguishing between normal and cancerous colonic tissue cells using hybridization of a DNA probe to RNA in the test sample.